Author Response: Neurology Education in 2035: The Neurology Future Forecasting Series
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We appreciate the comment by Dr. Das and welcome the opportunity to provide some thoughts about Artificial Intelligence (AI) in neurology education. We drafted this manuscript in the first half of 2022, and it was accepted in its final form in October 2022, a month before the launch of ChatGPT moved AI to the forefront of our collective consciousness. Although the principles of machine learning date back to the 1950s, the integration of AI into medical research and clinical care has been challenging and typically slower than predicted. We direct readers to the excellent Future Forecasting Series article by Jones and Kerber1 for a detailed and nuanced discussion of this issue. There have been many examples of potential applications of AI in all aspects of medical education, but there are still major limitations in the methodological frameworks to evaluate the effect of this work.2 AI will likely play a greater role in everything in 2035—including neurology education—and like every other technological innovation, it will have essential applications and serious shortcomings. Our goal as educators will be to ensure that the desire for efficiency and automation does not supplant the centrality of human relationships in our educational mission.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- Received April 7, 2023.
- Accepted in final form April 7, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen